Oxford Ledge
Search
Market prices for MBX are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
MBX Biosciences, Inc. Common Stock (NASDAQ: MBX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 03:14 UTC.
The company is a clinical-stage biopharmaceutical organization developing precision peptide therapies for endocrine and metabolic disorders using its proprietary PEP platform, which is designed to create peptides with extended duration, low peak-to-trough ratios, and less frequent dosing requirements. The lead product, canvuparatide, is a PTH peptide prodrug for chronic hypoparathyroidism that completed a Phase 2 trial and is expected to advance to Phase 3 in the third quarter of 2026.
Summarized from MBX Biosciences, Inc. Common Stock’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
Charts, 10-year financials, peer comparison, screening and portfolio tracking for MBX and 5,000+ tickers.
Create a free account — keep MBXGET /api/data?ticker=MBX
This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt